The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis

The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis

BackgroundAn increasing number of patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and develop progressive disease after receiving conventional treatments. In recent years, several novel therapies have been approved for later lines of therapy of previously treated NSCL...

Full description

Bibliographic Details
Main Authors:	Fazong Wu, Jingjing Song, Zhongwei Zhao, Xufang Huang, Jianting Mao, Jianfei Tu, Minjiang Chen, Weiqian Chen, Shiji Fang, Liyun Zheng, Xiaoxi Fan
Format:	Article
Language:	English
Published:	AIMS Press 2019-08-01
Series:	Mathematical Biosciences and Engineering
Subjects:	nsclc erlotinib pretreated patients meta-analysis
Online Access:	https://www.aimspress.com/article/10.3934/mbe.2019398?viewType=HTML

Similar Items

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
by: Minami Seigo, et al.
Published: (2012-07-01)

Acute Fatal Liver Toxicity under Erlotinib
by: Sabina Schacher-Kaufmann, et al.
Published: (2010-06-01)

Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA
by: Peipei Nie, et al.
Published: (2015-04-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2023-10-01)

Synergistic Effects of 2-Deoxy-D-Glucose and Cinnamic Acid with Erlotinib on NSCLC Cell Line
by: Wrood salim Al-khfajy, et al.
Published: (2023-11-01)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
by: Cavazzoni Andrea, et al.
Published: (2012-12-01)

Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer
by: Ge Sun, et al.
Published: (2022-01-01)

DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer
by: Tae Young Kim, et al.
Published: (2020-09-01)

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
by: Yukio Hosomi, et al.
Published: (2022-08-01)

Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells
by: Jisu Jeong, et al.
Published: (2022-03-01)

Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
by: Kathleen E. Spitz, MD, MBA, et al.
Published: (2022-07-01)

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer
by: Cong Xu, et al.
Published: (2023-05-01)

Russian multicenter retrospective study: preliminary data concerning clinical and molecular genetic characteristics in long-term responders to erlotinib
by: A V Smolin, et al.
Published: (2014-09-01)

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
by: Tatsuya Imabayashi, et al.
Published: (2019-02-01)

Erlotinib-induced dry eye
by: Rashmita Ravisankar, et al.
Published: (2023-01-01)

Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer
by: Liyan XU, et al.
Published: (2009-12-01)

A Clinical Observation of Concomitant Therapy of Erlotinib and Whole Brain Radiotherapy in Patients of NSCLC Combined with Brain Metastases
by: Lihong ZHANG, et al.
Published: (2009-12-01)

Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
by: Paul Zarogoulidis, et al.
Published: (2017-01-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
by: Wafa K. Fatani, et al.
Published: (2023-05-01)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012-06-01)

Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
by: Donglai Chen, et al.
Published: (2018-11-01)

Scalp acneiform rash caused by erlotinib: a case report
by: Zhang Qian, Zhang Xin, Wang Qian, Zhou Xiyuan, Zhang Lixia
Published: (2023-07-01)

Development and Application of an HPLC Method for Erlotinib Protein Binding Studies
by: Soheila Bolandnazar, et al.
Published: (2013-08-01)

Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
by: Haiqing YUAN, et al.
Published: (2009-07-01)

Spontaneous Healing of Corneal Perforation after Temporary Discontinuation of Erlotinib Treatment
by: Naoyuki Morishige, et al.
Published: (2014-01-01)

Tumor Cell-Specific Retention and Photodynamic Action of Erlotinib-Pyropheophorbide Conjugates
by: Erin C. Tracy, et al.
Published: (2022-09-01)

OCTA analysis of the effect of Erlotinib on corneal thickness in mice
by: Qing Yuan, et al.
Published: (2019-08-01)

Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients
by: Yuh-Min Chen, et al.
Published: (2015-03-01)

The ways of erlotinib resistance overcoming in treatment of patients with eGFr mutated nsClC
by: S V Orlov
Published: (2013-12-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
by: Jinhui TIAN, et al.
Published: (2009-12-01)

The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer
by: Baohui HAN, et al.
Published: (2009-12-01)

A Retrospective Analysis of Erlotinib and TP/GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer
by: Yongjuan WU, et al.
Published: (2009-12-01)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
by: Atakan Topcu, et al.
Published: (2022-10-01)

Cutaneous side effects during therapy with Erlotinib: Case report
by: Jovičić Sanja, et al.
Published: (2021-01-01)

Rhamnolipid-coated W/O/W double emulsion nanoparticles for efficient delivery of doxorubicin/erlotinib and combination chemotherapy
by: Yeeun Lee, et al.
Published: (2021-12-01)

Dramatic Improvement of Severe Cicatricial Ectropion after Discontinuing Long-Term Erlotinib Therapy in a Patient with Lung Cancer
by: Mehmet Serhat Mangan
Published: (2022-02-01)